The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Emma Lane is a Reader in Neuropharmacology at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University in Wales, UK. After a PhD at Kings College London and a post-doctoral research position at Lund University with Patrik Brundin and Angela Cenci, she moved to Cardiff University to work with Steve Dunnett and Anne Rosser in the Brain Repair Group. She established her own independent group within the School of Pharmacy and Pharmaceutical Sciences in 2009 focusing on modeling and understanding the side effects of current and novel therapeutic interventions for Parkinson’s disease in rodent models. In particular her work is providing an evidence base to optimizing cell and gene therapies alongside concurrent pharmacotherapy. With a long-held interest in public engagement and public involvement and as the lead for the BRAIN Involve PPI group she leads the LEARN (Listening to the Experiences of pARticipants on Neurosurgical trials) study group. This team are implementing a series of mixed methods studies, to collate the participant experience of clinical trials of new complex interventions for neurodegenerative diseases. This knowledge will be used inform the design of future trials, and delivery of therapies, to improve both information for participants and their families, as well as processes and outcome measures. This is being done collaboratively with the participants, those who hope to benefit most from these new innovations in treatment.